News
HCM
14.43
+0.91%
0.13
Weekly Report: what happened at HCM last week (1216-1220)?
Weekly Report · 3d ago
Oversold Conditions For HUTCHMED
NASDAQ · 12/16 16:54
Weekly Report: what happened at HCM last week (1209-1213)?
Weekly Report · 12/16 09:29
Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance
Benzinga · 12/13 07:38
Hutchmed to receive milestone payment from Takeda
TipRanks · 12/13 00:11
HUTCHMED TO RECEIVE MILESTONE PAYMENT FROM TAKEDA FOLLOWING FIRST EUROPEAN REIMBURSEMENT FOR FRUZAQLA® (FRUQUINTINIB)
Reuters · 12/13 00:00
Hutchmed announces BTD in China for Orpathys, Tagrisso combination
TipRanks · 12/12 10:35
HUTCHMED Granted Breakthrough Therapy Designation for Combination of ORPATHYS® and TAGRISSO® in Treating Advanced Non-Small Cell Lung Cancer
Barchart · 12/12 08:20
Reported Earlier, HUTCHMED's ORPATHYS and TAGRISSO Combo Gains Therapy Designation in China for Advanced Lung Cancer
Benzinga · 12/12 07:15
HUTCHMED: ORPATHYS And TAGRISSO Get Breakthrough Therapy Designation In China For NSCLC
NASDAQ · 12/12 05:02
HUTCHMED ANNOUNCES BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR ORPATHYS® AND TAGRISSO® COMBINATION IN CERTAIN LUNG CANCER PATIENTS AFTER DISEASE PROGRESSION ON EGFR INHIBITOR THERAPY
Reuters · 12/12 04:00
Weekly Report: what happened at HCM last week (1202-1206)?
Weekly Report · 12/09 09:28
HUTCHMED Receives NMPA Conditional Approval For TYVYT Combination In Advanced Endometrial Cancer
NASDAQ · 12/04 03:31
INNOVENT AND HUTCHMED JOINTLY ANNOUNCE NMPA CONDITIONAL APPROVAL FOR TYVYT® (SINTILIMAB INJECTION) IN COMBINATION WITH ELUNATE® (FRUQUINTINIB) FOR THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER
Reuters · 12/04 00:00
HUTCHMED and Innovent Announce First Regulatory Approval of Fruquintinib Combination Therapy with Sintilimab for Advanced Endometrial Cancer in China
Barchart · 12/03 14:24
HUTCHMED, Innovent's ELUNATE-TYVYT Combo Secures Approval In China For Endometrial Cancer
NASDAQ · 12/03 11:36
Hutchmed announces Elunate, Tyvyt NDA granted approval in China
TipRanks · 12/03 10:20
Hutchmed And Innovent Biologics Announce That Elunate (Fruquintinib) And Tyvyt (Sintilimab) Combination Has Received Conditional Approval In China For Advanced Endometrial Cancer With Mismatch Repair Proficient Tumors That Have Failed Prior Systemic Therapy And Are Not Candidates For Curative Surgery Or Radiation
Benzinga · 12/03 10:05
HUTCHMED AND INNOVENT JOINTLY ANNOUNCE NMPA CONDITIONAL APPROVAL FOR ELUNATE® (FRUQUINTINIB) IN COMBINATION WITH TYVYT® (SINTILIMAB INJECTION) FOR THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER
Reuters · 12/03 10:00
Weekly Report: what happened at HCM last week (1125-1129)?
Weekly Report · 12/02 09:28
More
Webull provides a variety of real-time HCM stock news. You can receive the latest news about Hutchmed (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.